Product Description
Autologous 2nd generation CD19/CD20-directed CAR-T cells. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05421663)
Mechanisms of Action: CAR-T, CD19, CD20
Novel Mechanism: Yes
Modality: Autologous CAR-T
Route of Administration: Intravenous
FDA Designation: Fast Track - Hodgkin Lymphoma|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: Cellular Biomedicine Group
Clinical Description
Countries in Clinic: Australia, Canada, China, Denmark, Netherlands, South Korea, Spain, United Kingdom, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Johnson & Johnson presented P1 Lymphoma results on 2025-06-13 for Prizloncabtagene autoleucel
Highest Development Phases
Phase 2: Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05421663 |
90014496LYM1001 | P2 |
Active, not recruiting |
Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma |
2041-07-30 |
42% |
2026-08-29 |
Primary Completion Date|Primary Endpoints |
NCT07875413 |
ABZT-121 | P2 |
Not yet recruiting |
Diffuse Large B-Cell Lymphoma|Follicular Lymphoma |
2029-06-01 |
50% |
2026-10-16 |
Primary Endpoints|Treatments |
NCT05800977 |
ELEVATION | P2 |
Recruiting |
Lymphoma, B-Cell |
2027-03-31 |
2026-01-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |